Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-07028-3
Abstract: Purpose There is limited real-world evidence around use of proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9i) among US older adults. This study examined baseline characteristics of fee-for-service (FFS) Medicare beneficiaries newly initiating PCSK9i therapy during… read more here.
Keywords: period; medicare beneficiaries; beneficiaries initiating; baseline ... See more keywords